Treatment of high risk and oligo-metastatic prostate cancer
Poster Session 02
-
Location:Room Amsterdam, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Institutes: 1University Hospital Bern, Dept. of Urology, Bern, Switzerland, 2University Hospital Bern, Institute of Pathology, Bern, Switzerland
Institutes: 1University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, 2University Medical Center, Dept. of Urology, Hamburg, Germany, 3University Medical Center, Martini-Clinic, Hamburg, Germany
Institutes: 1King’s College London, Dept. of Cancer Epdiemiology, London, United Kingdom, 2Guy’s and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 3Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 4Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden
Institutes: 1Magna Graecia University, Dept. of Urology, Catanzaro, Italy, 2Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Molinette Hospital, Dept. of Urology, Turin, Italy, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital of Bern, Dept. of Urology, Bern, Switzerland
Institutes: 1Universitätsklinikum Hamburg-Eppendorf, Martini Clinic and Dept. of Urology, Hamburg, Germany, 2Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada
Institutes: 1University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, 2University of Tübingen, Dept. of Urology, Tübingen, Germany, 3University Medical Center Eppendorf, Dept. of Radiooncology, Hamburg, Germany, 4European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Hamburg, Germany
Institutes: 1Vita-Salute University San Raffaele; Magna Graecia University, Dept. of Urology, Milan, Italy, 2University Hospital of Leuven, Dept. of Urology, Leuven, Belgium, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4University of Turin, Dept. of Urology, Turin, Italy, 5Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 6University Hospital of Bern, Dept. of Urology, Bern, Switzerland
Institutes: 1Uniklinik Köln, Dept. of Urology, Cologne, Germany, 2Vita Salute San Raffaele University, Urological Research Institute, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Universitätsklinik Wien, Dept. of Urology, Vienna, Austria
Institutes: 1Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, 2National Health Insurance Corporation Ilsan Hospital, Dept. of Urology and Urological Science Institute, Goyang, South Korea, 3Inje University College of Medicine, Dept. of Urology and Urological Science Institute, Gimhae, South Korea